Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.

Alembic Therapeutics Acquires NUVESSA® for Women's Health Portfolio

Alembic Therapeutics, LLC has acquired NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc., an FDA-approved prescription medication for bacterial vaginal infections in females 12 years and older. This strategic acquisition expands Alembic Therapeutics' women’s health portfolio and aims to increase patient access to proven treatment options. Alembic Therapeutics will now manage the commercialization and distribution of NUVESSA in the United States, ensuring its continued availability through retail and specialty pharmacies.

• Alembic Therapeutics, LLC's acquisition of NUVESSA® from Exeltis USA, Inc. significantly bolsters its women's health portfolio. This move underscores Alembic's commitment to delivering high-quality pharmaceutical products and innovative healthcare solutions, specifically by expanding access to an established treatment for bacterial vaginal infections.
• NUVESSA® is an FDA-approved metronidazole vaginal gel (1.3%), designed as a convenient single-dose, pre-filled disposable applicator. Each applicator delivers approximately 5g of gel containing 65mg of metronidazole, administered once daily at bedtime intravaginally for bacterial vaginosis in females 12 years and older.
• With this transaction, Alembic Therapeutics assumes full responsibility for the commercialization and distribution of NUVESSA® throughout the United States. The medication will remain available nationwide via retail and specialty pharmacy channels, ensuring healthcare providers can continue prescribing it in accordance with approved prescribing information.

Understanding NUVESSA's Safety and Tolerability Profile

Clinical studies consistently demonstrate that metronidazole vaginal gel exhibits a superior safety and tolerability profile compared to oral formulations. In comparative trials, intravaginal administration resulted in significantly fewer adverse events overall, with particularly notable reductions in systemic side effects. A 2009 randomized controlled trial of 263 patients showed that nausea occurred in only 10.2% of patients receiving intravaginal metronidazole versus 30.4% with oral administration, while abdominal pain was reported in 16.8% versus 31.9% respectively. Similarly, metallic taste, a characteristic side effect of metronidazole, occurred in 8.8% of intravaginal cases compared to 17.9% with oral treatment.

The safety profile of metronidazole vaginal gel across different formulations has been well-established in bacterial vaginosis treatment studies. Single-dose metronidazole vaginal gel 1.3% demonstrated no serious adverse events, with adverse event incidence similar to vehicle gel controls. Multi-day regimens using 0.75% metronidazole gel administered twice daily for 5 days were characterized as producing uncommon and mild side effects, leading investigators to describe the therapy as effective, safe, and well-tolerated. Combination formulations, including pessaries containing 750 mg metronidazole with miconazole, were also reported as well-tolerated by patients.

Patient satisfaction and compliance outcomes further support the favorable tolerability profile of vaginal metronidazole formulations. Studies consistently show higher patient satisfaction with intravaginal treatment compared to oral alternatives, with the improved tolerability likely contributing to better treatment compliance. The primary safety consideration identified across studies was an increased incidence of post-treatment vulvovaginal candidiasis in approximately 30% of subjects treated with metronidazole vaginal gel, though this difference was not statistically significant when compared to other treatment modalities. Beyond STD prevention benefits observed in prophylactic use studies, the localized delivery approach of vaginal gel formulations effectively minimizes systemic exposure while maintaining therapeutic efficacy.

Key Challenges in Current Bacterial Vaginosis Treatment

Current bacterial vaginosis treatment faces several interconnected challenges that significantly impact clinical outcomes and patient care. Despite the availability of effective antibiotics like metronidazole and clindamycin, treatment failures and recurrent infections remain prevalent, creating substantial therapeutic hurdles for clinicians and patients alike.

• High recurrence rates persist despite initial treatment success - Studies demonstrate that 23.1% of cases relapse during follow-up after metronidazole treatment, with more than half of bacterial vaginosis patients experiencing recurrence after antibiotic therapy, and recurrence rates ranging from 25.5% with suppressive metronidazole gel therapy to 75% with placebo during 28-week follow-up periods

• Widespread antibiotic resistance limits treatment efficacy - At baseline, 64% of Gardnerella isolates show resistance to metronidazole using CLSI criteria, rising to 80% after treatment by 12 weeks, with 87.5% of samples demonstrating metronidazole resistance and Fannyhessea vaginae maintaining resistance rates of 78-91% across clinical visits

• Biofilm formation by pathogenic bacteria creates treatment-resistant infections - Gardnerella vaginalis biofilm formation contributes significantly to high recurrence rates, with established biofilms showing minimal response to standard antibiotics, requiring minimum biofilm eradication concentrations exceeding 256 μg/ml for metronidazole and >2 μg/ml for clindamycin

• Diagnostic limitations hinder targeted treatment approaches - Bacterial species causing bacterial vaginosis generally cannot be cultured using conventional methods, making it impractical to use culture-guided therapy, with Gram-positive cocci presence in pretreatment smears serving as a predictor of metronidazole treatment failure in all 16 documented cases

• Treatment compliance challenges affect therapeutic outcomes - Current regimens requiring frequent administration create compliance difficulties for patients, potentially contributing to treatment failures and resistance development through incomplete therapeutic courses

• Limited evidence supports alternative therapeutic approaches - The use of antiseptics and disinfectants for bacterial vaginosis treatment remains poorly studied with methodologically flawed research, providing insufficient evidence to advocate for these agents despite some studies suggesting comparable efficacy to standard antibiotics

Expanding Alembic's Portfolio: NUVESSA's Broader Potential

Metronidazole vaginal gel is being investigated beyond bacterial vaginosis for several additional indications, with clinical trials employing diverse intervention models. These studies demonstrate the potential for expanded therapeutic applications of topical metronidazole formulations in gynecological and surgical settings.

• Mixed vaginal infections: An acid buffering bioadhesive vaginal gel containing metronidazole combined with clotrimazole and Lactobacillus spores was developed to treat polymicrobial infections, utilizing bioadhesive polymers for 12-13 hour vaginal retention with superior antimicrobial efficacy compared to commercial systems

• Trichomoniasis treatment: A randomized, open-label pilot study compared 0.75% metronidazole vaginal gel twice daily for 7 days versus oral metronidazole, though vaginal administration showed inferior efficacy (44% cure rate) compared to oral therapy (100% cure rate)

• Surgical site infection prophylaxis: Randomized controlled trials in hysterectomy patients used single-dose 0.75% metronidazole vaginal gel administered preoperatively, demonstrating reduced infection rates (5.8% vs 11.6% in controls) with follow-up extending to 6 weeks post-surgery

• Pregnancy-related vaginal infections: An observational study in 600 pregnant women at 28 weeks gestation employed topical metronidazole-clotrimazole combination therapy for 6 days, achieving 72% eradication rates and reducing preterm premature rupture of membrane risks to baseline levels

• Preoperative vaginal preparation: Clinical trials investigated combination therapy with 500mg metronidazole and 100mg miconazole administered twice daily for 7 days before elective hysterectomy, significantly reducing vaginal cuff infections compared to untreated controls (2.1% vs 8.2%)

NUVESSA Acquisition: Bolstering Single-Dose BV Treatment

Alembic Therapeutics' recent acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA marks a calculated expansion into the women's health market, specifically targeting bacterial vaginosis (BV). This move is significant because NUVESSA offers an FDA-approved, single-dose intravaginal treatment for BV, a condition that affects a substantial number of women and is linked to increased risks of upper genital tract and sexually transmitted infections. The convenience of a single-dose regimen is a powerful differentiator, as it can substantially improve patient adherence compared to traditional multi-day oral or topical antibiotic courses, potentially leading to better real-world outcomes.

However, the landscape for BV treatment is not without its complexities. While metronidazole remains a cornerstone therapy, research highlights persistent challenges. Notably, certain clades of Gardnerella vaginalis, a bacterium strongly associated with BV, have been identified as intrinsically resistant to metronidazole. Furthermore, BV is characterized by high recurrence rates, even after successful initial treatment, suggesting that a single course of therapy, regardless of its convenience, may not provide a definitive long-term solution for all patients.

For Alembic, this acquisition strategically bolsters their women's health portfolio with a proven product. The company's success will hinge on effectively communicating NUVESSA's benefits, particularly its single-dose convenience and established efficacy, to both healthcare providers and patients. Yet, they must also navigate a competitive market that includes other metronidazole formulations, alternative antibiotics like clindamycin, and emerging adjunctive or rescue therapies such as intravaginal boric acid for recurrent cases. Looking ahead, Alembic may need to consider strategies that address the broader challenges of antimicrobial resistance and BV recurrence, perhaps through patient education on vaginal health maintenance or by exploring future combination therapies to sustain NUVESSA's market relevance and impact.